Literature DB >> 28211944

Bayesian response-adaptive designs for basket trials.

Steffen Ventz1,2, William T Barry2,3, Giovanni Parmigiani2,4, Lorenzo Trippa2,4.   

Abstract

We develop a general class of response-adaptive Bayesian designs using hierarchical models, and provide open source software to implement them. Our work is motivated by recent master protocols in oncology, where several treatments are investigated simultaneously in one or multiple disease types, and treatment efficacy is expected to vary across biomarker-defined subpopulations. Adaptive trials such as I-SPY-2 (Barker et al., 2009) and BATTLE (Zhou et al., 2008) are special cases within our framework. We discuss the application of our adaptive scheme to two distinct research goals. The first is to identify a biomarker subpopulation for which a therapy shows evidence of treatment efficacy, and to exclude other subpopulations for which such evidence does not exist. This leads to a subpopulation-finding design. The second is to identify, within biomarker-defined subpopulations, a set of cancer types for which an experimental therapy is superior to the standard-of-care. This goal leads to a subpopulation-stratified design. Using simulations constructed to faithfully represent ongoing cancer sequencing projects, we quantify the potential gains of our proposed designs relative to conventional non-adaptive designs.
© 2017, The International Biometric Society.

Entities:  

Keywords:  Adaptive randomization; Bayesian hierarchical models; Master protocols; Ulti-arm clinical trials

Mesh:

Year:  2017        PMID: 28211944     DOI: 10.1111/biom.12668

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  9 in total

1.  Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes.

Authors:  Nan Chen; J Jack Lee
Journal:  Biom J       Date:  2018-12-03       Impact factor: 2.207

2.  Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.

Authors:  Steffen Ventz; Matteo Cellamare; Giovanni Parmigiani; Lorenzo Trippa
Journal:  Biostatistics       Date:  2018-04-01       Impact factor: 5.899

3.  Variance prior specification for a basket trial design using Bayesian hierarchical modeling.

Authors:  Kristen M Cunanan; Alexia Iasonos; Ronglai Shen; Mithat Gönen
Journal:  Clin Trials       Date:  2018-12-07       Impact factor: 2.486

Review 4.  Novel Clinical Trial Designs in Neuro-Oncology.

Authors:  Anurag Saraf; Lorenzo Trippa; Rifaquat Rahman
Journal:  Neurotherapeutics       Date:  2022-08-15       Impact factor: 6.088

5.  Inference in response-adaptive clinical trials when the enrolled population varies over time.

Authors:  Massimiliano Russo; Steffen Ventz; Victoria Wang; Lorenzo Trippa
Journal:  Biometrics       Date:  2021-10-21       Impact factor: 1.701

6.  Reporting of master protocols towards a standardized approach: A systematic review.

Authors:  Ellie G Siden; Jay Jh Park; Michael J Zoratti; Louis Dron; Ofir Harari; Kristian Thorlund; Edward J Mills
Journal:  Contemp Clin Trials Commun       Date:  2019-07-04

7.  A cross-cutting approach to enhancing clinical trial site success: The Department of Veterans Affairs' Network of Dedicated Enrollment Sites (NODES) model.

Authors:  Debra L Condon; Danielle Beck; Tawni Kenworthy-Heinige; Karen Bratcher; Meghan O'Leary; Aliya Asghar; Cyenthia Willis; Marcus R Johnson; Grant D Huang
Journal:  Contemp Clin Trials Commun       Date:  2017-03-29

8.  Master protocol trials in oncology: Review and new trial designs.

Authors:  Akihiro Hirakawa; Junichi Asano; Hiroyuki Sato; Satoshi Teramukai
Journal:  Contemp Clin Trials Commun       Date:  2018-08-24

9.  Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

Authors:  Marlieke E A de Kraker; Harriet Sommer; Femke de Velde; Isaac Gravestock; Emmanuel Weiss; Alexandra McAleenan; Stavros Nikolakopoulos; Ohad Amit; Teri Ashton; Jan Beyersmann; Leonhard Held; Andrew M Lovering; Alasdair P MacGowan; Johan W Mouton; Jean-François Timsit; David Wilson; Martin Wolkewitz; Esther Bettiol; Aaron Dane; Stephan Harbarth
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.